Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021)
Agios Pharmaceuticals (AGIO) reported Liabilities from Discontinued Operations of 34533000.0 for Q1 2021, down 86.78% quarter-over-quarter from 261269000.0 in Q4 2020.
Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021) Analysis & Trends
Agios Pharmaceuticals has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 34533000.0 in Q1 2021.
- For the quarter ending Q1 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 34533000.0; the trailing twelve-month figure through Mar 2021 stood at 34533000.0 (changed N/A YoY), and the FY2020 full-year result was 261269000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2021 stood at 34533000.0, down from 261269000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 261269000.0 in Q4 2020, with the low at 34533000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 34.53 Mn |
| Mar 31, 2021 | 34.53 Mn |
| Dec 31, 2020 | 261.27 Mn |
| Dec 31, 2020 | 261.27 Mn |